

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Previously Presented): A biologically pure strain of *Lactobacillus* sp. BC-Y009 (KCTC-0774BP).

Claim 2. (Previously Presented): A biologically pure strain of *Acetobacter* sp. BC-Y058 (KCTC-0773BP).

Claim 3. (Currently Amended): A pharmaceutical composition comprising at least one microorganism selected from the group consisting of *Acetobacter* BC-Y058 and *Lactobacillus* BC-Y009 ~~*Acetobacter* sp., *Leuconostoc* sp., *Bacillus* sp., *Lactobacillus* sp., *Streptococcus* sp., *Bifidobacterium* sp., *Lactococcus* sp. and *Pediococcus* sp.~~ bacteria in an amount effective to ~~prevent or~~ treat obesity and a pharmaceutically acceptable carrier, wherein the microorganism is capable of producing an extracellular polysaccharide.

Claim 4-6. (Cancelled)

Claim 7. (Original): The pharmaceutical composition according to claim 3, which is a formulation suitable for oral administration.

Claim 8. (Original): The pharmaceutical composition according to claim 3, which is a formulation coated with enteric coating materials.

Claim 9. (Original): The pharmaceutical composition according to claim 7, which is a formulation coated with enteric coating materials.

Claim 10. (Currently Amended): A pharmaceutical composition comprising at least one microorganism selected from the group consisting of *Acetobacter* BC-Y058 and *Lactobacillus* BC-Y009 ~~*Acetobacter* sp., *Leuconostoc* sp., *Bacillus* sp., *Lactobacillus* BC-Y009, *Lactobacillus brevis*, *Lactobacillus helveticus*, *Lactobacillus bulgaricus*, *Lactobacillus casei*, *Lactobacillus kefir*, *Lactobacillus keriranoferiens*, *Lactobacillus bifidus*, *Lactobacillus sake*, *Lactobacillus reuteri*, *Lactobacillus lactis*, *Lactobacillus delbrueckii*, *Lactobacillus helveticus* glucos var. *jugurti*, *Streptococcus* sp., *Bifidobacterium* sp., *Lactococcus* sp. and~~

~~*Pediococcus* sp. bacteria~~ in an amount effective to ~~prevent or~~ treat diabetes mellitus and a pharmaceutically acceptable carrier, ~~wherein the microorganism is capable of producing an extracellular polysaccharide.~~

Claim 11-13. (Cancelled)

Claim 14. (Original): The pharmaceutical composition according to claim 10, which is a formulation suitable for oral administration.

Claim 15. (Original): The pharmaceutical composition according to claim 10, which is a formulation coated with enteric coating materials.

Claim 16. (Currently Amended): A method for ~~preventing or~~ treating obesity, comprising administering to a subject in need thereof a pharmaceutical composition comprising at least one microorganism selected from the group consisting of *Acetobacter* BC-Y058 and *Lactobacillus* BC-Y009 ~~*Acetobacter* sp., *Leuconostoc* sp., *Bacillus* sp., *Lactobacillus* sp., *Streptococcus* sp., *Bifidobacterium* sp., *Lactococcus* sp. and *Pediococcus* sp.~~ bacteria in an amount effective to ~~prevent or~~ treat obesity and a pharmaceutically acceptable carrier, ~~wherein the microorganism is capable of producing polysaccharide.~~

Claim 17-19. (Cancelled)

Claim 20. (Original): The method according to claim 16, wherein the pharmaceutical composition is a formulation suitable for oral administration.

Claim 21. (Original): The method according to claim 16, wherein the pharmaceutical composition is a formulation coated with enteric coating materials.

Claim 22. (Original): The method according to claim 20, wherein the pharmaceutical composition is a formulation coated with enteric coating materials.

Claim 23. (Currently Amended): A method for ~~preventing or~~ treating diabetes mellitus, comprising administering to a subject in need thereof a pharmaceutical composition comprising at least one microorganism selected from the group consisting of *Acetobacter* BC-Y058 and *Lactobacillus* BC-Y009 ~~*Acetobacter* sp., *Leuconostoc* sp., *Bacillus* sp., *Lactobacillus* BC-Y009, *Lactobacillus brevis*, *Lactobacillus helveticus*, *Lactobacillus*~~

~~*bulgaricus*, *Lactobacillus casei*, *Lactobacillus kefir*, *Lactobacillus keriranoferiens*,
Lactobacillus bifidus, *Lactobacillus sake*, *Lactobacillus reuteri*, *Lactobacillus lactis*,
Lactobacillus delbrueckii, *Lactobacillus helveticus* glucos var. *jugurti*, *Streptococcus sp.*,
Bifidobacterium sp., *Lactococcus sp.* and *Pediococcus sp.* bacteria in an amount effective to
prevent or treat diabetes mellitus and a pharmaceutically acceptable carrier, wherein the
microorganism is capable of producing polysaccharide.~~

Claim 24-26. (Cancelled)

Claim 27. (Original): The method according to claim 23, wherein the pharmaceutical composition is a formulation suitable for oral administration.

Claim 28. (Original): The method according to claim 23, wherein the pharmaceutical composition is a formulation coated with enteric coating materials.

Claim 29. (Currently Amended): A method for controlling ~~or preventing~~ weight gain, comprising administering to a subject in need thereof a pharmaceutical composition comprising at least one microorganism selected from the group consisting of *Acetobacter* BC-Y058 and *Lactobacillus* BC-Y009 ~~*Acetobacter sp.*, *Leuconostoc sp.*, *Bacillus sp.*, *Lactobacillus sp.*, *Streptococcus sp.*, *Bifidobacterium sp.*, *Lactococcus sp.* and *Pediococcus sp.* bacteria~~ in an effective amount and a pharmaceutically acceptable carrier, ~~wherein the microorganism is capable of producing polysaccharide.~~

Claim 30. (Cancelled)

Claim 31. (Original): The method according to claim 29, wherein the pharmaceutical composition is suitable for oral administration.

Claim 32. (Original): The method according to claim 29, wherein the pharmaceutical composition is coated with enteric coating materials.

Claims 33-36. (Cancelled)

Claim 37. (Currently Amended): A method for controlling blood glucose level, comprising administering to a subject in need thereof a pharmaceutical composition comprising at least one microorganism selected from the group consisting of *Acetobacter* BC-

~~Y058 and Lactobacillus BC-Y009 Acetobacter sp., Leuconostoc sp., Bacillus sp., Lactobacillus sp., Streptococcus sp., Bifidobacterium sp., Lactococcus sp. and Pedioecoccus sp. bacteria in an effective amount and a pharmaceutically acceptable carrier, wherein the microorganism is capable of producing polysaccharide.~~

Claim 38. (Cancelled)

Claim 39. (Original): The method according to claim 37, wherein the pharmaceutical composition is suitable for oral administration.

Claim 40. (Original): The method according to claim 37, wherein the pharmaceutical composition is coated with enteric coating materials.

Claim 41. (Original): The method according to claim 37, wherein a normal blood glucose level is not affected.

Claim 42. (Currently Amended): A method for controlling absorption of blood lipid, comprising ~~comprising~~ administering to a subject in need thereof a pharmaceutical composition comprising at least one microorganism selected from the group consisting of Acetobacter BC-Y058 and Lactobacillus BC-Y009 ~~Acetobacter sp., Leuconostoc sp., Bacillus sp., Lactobacillus sp., Streptococcus sp., Bifidobacterium sp., Lactococcus sp. and Pedioecoccus sp.~~ bacteria in an effective amount and a pharmaceutically acceptable carrier, ~~wherein the microorganism is capable of producing polysaccharide.~~

Claim 43. (Cancelled)

Claim 44. (Original): The method according to claim 42, wherein the pharmaceutical composition is suitable for oral administration.

Claim 45. (Original): The method according to claim 42, wherein the pharmaceutical composition is coated with enteric coating materials.

Claim 46. (Previously Presented): The pharmaceutical composition according to claim 3, wherein the microorganism is capable of converting an oligosaccharide into a polysaccharide.

Claim 47. (Previously Presented): The pharmaceutical composition according to claim 10, wherein the microorganism is capable of converting an oligosaccharide into a polysaccharide.